Schedule 13G ownership disclosure

Amylyx Pharmaceuticals Inc

Common Stock, $0.0001 par value per share · CUSIP: 03237H101

Event date: 2025-11-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Commodore Capital LP

    Shares: 5,650,000.00 · Class: 5.1%

  • Commodore Capital Master LP

    Shares: 5,650,000.00 · Class: 5.1%

  • Robert Egen Atkinson

    Shares: 5,650,000.00 · Class: 5.1%

  • Michael Kramarz

    Shares: 5,650,000.00 · Class: 5.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001831942-25-000033
Form type
SCHEDULE 13G
Filer
Amylyx Pharmaceuticals, Inc.
CIK
CIK 1658551
Filed
Nov 17, 2025
Reporting period
Nov 10, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub